Skip to main content

Pfizer’s Stock Is Down 44% YTD As Woes Continue

Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.